{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(6)"],"submitter":["Heidrich B"],"pubmed_abstract":["<h4>Unlabelled</h4>Although sofosbuvir has been approved for patients with genotypes 2/3 (G2/3), many parts of the world still consider pegylated Interferon alpha (P) and ribavirin (R) as standard of care for G2/3. Patients with rapid virological response (RVR) show response rates >80%. However, SVR (sustained virological response) in non-RVR patients is not satisfactory. Longer treatment duration may be required but evidence from prospective trials are lacking. A total of 1006 chronic HCV genotype 2/3 patients treated with P/R were recruited into a German HepNet multicenter screening registry. Of those, only 226 patients were still HCV RNA positive at week 4 (non-RVR). Non-RVR patients with ongoing response after 24 weeks P-2b/R qualified for OPTEX, a randomized trial investigating treatm"],"journal":["PloS one"],"pagination":["e0128069"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4461366"],"repository":["biostudies-literature"],"pubmed_title":["Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial."],"pmcid":["PMC4461366"],"pubmed_authors":["Naumann U","Heidrich B","Gonnermann A","Kraus MR","Hardtke S","Boker KH","Moller B","Manns MP","Cordes HJ","Koch A","Schuchmann M","Roggel C","Klinker H","Trein A","Wedemeyer H","Cornberg M","Rossle M","Stoehr A"],"additional_accession":[]},"is_claimable":false,"name":"Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial.","description":"<h4>Unlabelled</h4>Although sofosbuvir has been approved for patients with genotypes 2/3 (G2/3), many parts of the world still consider pegylated Interferon alpha (P) and ribavirin (R) as standard of care for G2/3. Patients with rapid virological response (RVR) show response rates >80%. However, SVR (sustained virological response) in non-RVR patients is not satisfactory. Longer treatment duration may be required but evidence from prospective trials are lacking. A total of 1006 chronic HCV genotype 2/3 patients treated with P/R were recruited into a German HepNet multicenter screening registry. Of those, only 226 patients were still HCV RNA positive at week 4 (non-RVR). Non-RVR patients with ongoing response after 24 weeks P-2b/R qualified for OPTEX, a randomized trial investigating treatm","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015","modification":"2026-05-02T16:55:38.041Z","creation":"2019-03-26T23:33:12Z"},"accession":"S-EPMC4461366","cross_references":{"pubmed":["26057627"],"doi":["10.1371/journal.pone.0128069"]}}